Biology of Blood and Marrow Transplantation
Volume 14, Issue 12 , Pages 1401-1407 , December 2008

Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial

  • Muzaffar H. Qazilbash

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • Corresponding Author InformationCorrespondence and reprint requests: Muzaffar H. Qazilbash, MD, Department of Blood and Marrow Transplantation, UT-M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030.
    • ,
  • Rima M. Saliba

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Yago Nieto

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Gaurav Parikh

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Matteo Pelosini

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Fatima B. Khan

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Roy B. Jones

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Chitra Hosing

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Floralyn Mendoza

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Donna M. Weber

      Affiliations

    • Department of Lymphoma and Myeloma, UT M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Michael Wang

      Affiliations

    • Department of Lymphoma and Myeloma, UT M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Uday Popat

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Amin Alousi

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Paolo Anderlini

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Richard E. Champlin

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy
    • ,
  • Sergio Giralt, MD

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy

Received 30 August 2008 ,Accepted 23 September 2008.

  • Image Result

    Kaplan-Meier estimates for OS and PFS probability for all 48 patients treated on the protocol.

    Kaplan-Meier estimates for OS and PFS probability for all 48 patients treated on the protocol.

  • Image Result

    (A) Kaplan-Meier estimates for OS probability according to randomization to 3 treatment arms (arm 1 = no ATO, arm 2 = ATO 0.15 mg/kg, arm 3 = ATO 0.25 mg/kg). (B) Kaplan-Meier estimates for PFS probab

    (A) Kaplan-Meier estimates for OS probability according to randomization to 3 treatment arms (arm 1 = no ATO, arm 2 = ATO 0.15 mg/kg, arm 3 = ATO 0.25 mg/kg). (B) Kaplan-Meier estimates for PFS probability according to randomization to 3 treatment arms (arm 1 = no ATO, arm 2 = ATO 0.15 mg/kg, arm 3 = ATO 0.25 mg/kg).

  • Image Result
    Impact of ATO dose on melphalan AUC on the days of melphalan administration. AUC = area under the curve; DL1 = dose level 1/no ATO; DL2 = dose level 2/ATO 0.15 mg/kg; DL3 = dose level 3/ATO 0.25 mg/kg

    Impact of ATO dose on melphalan AUC on the days of melphalan administration. AUC = area under the curve; DL1 = dose level 1/no ATO; DL2 = dose level 2/ATO 0.15 mg/kg; DL3 = dose level 3/ATO 0.25 mg/kg.

 Financial disclosure: See Acknowledgments on page 1406.

PII: S1083-8791(08)00418-7

doi: 10.1016/j.bbmt.2008.09.019

Biology of Blood and Marrow Transplantation
Volume 14, Issue 12 , Pages 1401-1407 , December 2008

Article Tools

* Image Usage & Resolution